2024
Effect of BCG vaccination against Mycobacterium tuberculosis infection in adult Brazilian health-care workers: a nested clinical trial
dos Santos P, Messina N, de Oliveira R, da Silva P, Puga M, Dalcolmo M, dos Santos G, de Lacerda M, Jardim B, de Almeida e Val F, Curtis N, Andrews J, Croda J. Effect of BCG vaccination against Mycobacterium tuberculosis infection in adult Brazilian health-care workers: a nested clinical trial. The Lancet Infectious Diseases 2024, 24: 594-601. PMID: 38423021, PMCID: PMC11111441, DOI: 10.1016/s1473-3099(23)00818-6.Peer-Reviewed Original ResearchConceptsQuantiFERON-TB GoldPlacebo groupEffect of BCG vaccinationBCG vaccinationBCG groupBCG-DenmarkHealth-care workersNegative baseline resultsMonths of treatmentMycobacterium tuberculosis infectionAdult pulmonary tuberculosisQuantiFERON-TBMedian ageRandomised controlled trialsPulmonary tuberculosisNo significant differenceEfficacy outcomesTuberculosis infectionClinical trialsControlled trialsEffect of vaccinationTreatment drugsTuberculosis preventionSubstudySignificant difference
2023
Seroprevalence Of SARS-COV-2 infection in asymptomatic indigenous from the largest Brazilian periurban area
de Oliveira L, Dos Santos Barbosa M, Leite Torres A, Croda M, Oliveira da Silva B, Dos Santos P, Rossoni R, Machado L, Croda J, Maymone Gonçalves C, Marques M, da Silva Ferreira T, Sardi S, Campos G, de Almeida G, Alves Gomes M, Marchioro S, Simionatto S. Seroprevalence Of SARS-COV-2 infection in asymptomatic indigenous from the largest Brazilian periurban area. PLOS ONE 2023, 18: e0295211. PMID: 38134187, PMCID: PMC10745159, DOI: 10.1371/journal.pone.0295211.Peer-Reviewed Original ResearchConceptsEnzyme-linked immunosorbent assayCoronaVac inactivated vaccinesSARS-CoV-2SARS-CoV-2 infectionEnzyme-linked immunosorbent assay methodMedian ageSARS-CoV-2 antibodiesSeroprevalence of SARS-CoV-2 antibodiesSeroprevalence of SARS-CoV-2Asymptomatic individualsRapid testSeropositivity rateBlood samplesEthnic groupsElevated seroprevalenceImmunosorbent assaySeroprevalence of SARS-CoV-2 infectionSARS-CoV-2 rapid testSeropositivityAntibodiesVulnerable ethnic groupsSeroprevalence
2022
HTLV infection in Brazil’s second-largest indigenous reserve
Amianti C, Bandeira L, Cesar G, Weis-Torres S, Tanaka T, Machado I, Gonçalves C, Simionatto S, Schnaufer E, Freitas F, Vallinoto A, Croda J, Motta-Castro A. HTLV infection in Brazil’s second-largest indigenous reserve. Scientific Reports 2022, 12: 16701. PMID: 36202887, PMCID: PMC9537150, DOI: 10.1038/s41598-022-21086-7.Peer-Reviewed Original ResearchConceptsHTLV infectionHTLV-1HTLV-2HTLV-1-associated myelopathyAdult T-cell leukemia/lymphomaHuman T-lymphotropic virus 1T-cell leukemia/lymphomaChronic inflammatory neurological diseaseHTLV-1 prevalenceInflammatory neurological diseasesHTLV-2 infectionAggressive malignant diseaseLeukemia/lymphomaEnzyme-linked immunosorbentMedian agePregnant populationMalignant diseaseBlood donorsStudy populationDrug usersNeurological diseasesCosmopolitan subtypeWestern blotSerum samplesDisease
2021
Risk Factors for Death Among 120,804 Hospitalized Patients with Confirmed COVID-19 in São Paulo, Brazil
da Silva P, de Oliveira S, Escalante J, Almiron M, Tsuha D, Sato H, Menezes P, de Paula R, D’Agostini T, Croda J. Risk Factors for Death Among 120,804 Hospitalized Patients with Confirmed COVID-19 in São Paulo, Brazil. American Journal Of Tropical Medicine And Hygiene 2021, 105: 88-92. PMID: 34061773, PMCID: PMC8274770, DOI: 10.4269/ajtmh.20-1598.Peer-Reviewed Original ResearchConceptsCOVID-19Confirmed COVID-19Characteristics of patientsChronic lung diseaseIntensive care unitChronic cardiovascular diseaseChronic neurological diseaseMore comorbiditiesClinical characteristicsDiabetes mellitusMedian ageCare unitLung diseaseRisk factorsCardiovascular diseaseHigh riskSevere casesElderly individualsPatientsNeurological diseasesSurvival analysisCoronavirus diseaseDiseaseSão PauloDeath